I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am a Healthcare Professional outside the US and UK Read more
I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

I am not a Healthcare Professional and I am outside the US and the UK Read more
Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ASCO, Chicago, IL, USA, 1-5 June 2018

DLT Definitions

DLT Definition

First-in-human Phase I trial of BI 836880, a vascular endothelial growth factor/angiopoietin-2-blocking Nanobody®, given every 3 weeks in patients with advanced/metastatic solid tumors

Christophe Le Tourneau, Rainer Claus, Francesco Ricci, Björn Hackanson, Christoph Rummelt, Oliver Fietz, Thomas Arnhold, Dooti Roy, Zohra Oum’Hamed, Ralph Fritsch

Le Tourneau et al ASCO 2018 poster

Related information

ASCO 2018

Find information on Boehringer Ingelheim's clinical data and activities at ASCO 2018

 

VEGF/Ang2 inhibitor

Find out more about BI’s investigational VEGF/Ang2 inhibitor
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY.

 

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.